667 related articles for article (PubMed ID: 23916461)
1. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
4. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation.
López-Gasco P; Iglesias I; Benedí J; Lozano R; Teijón JM; Blanco MD
J Microencapsul; 2011; 28(5):417-29. PubMed ID: 21736526
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.
Sun B; Feng SS
Nanomedicine (Lond); 2009 Jun; 4(4):431-45. PubMed ID: 19505246
[TBL] [Abstract][Full Text] [Related]
8. Characterization and in-vitro bioactivity evaluation of paclitaxel-loaded polyester nanoparticles.
López-Gasco P; Iglesias I; Benedí J; Lozano R; Blanco MD
Anticancer Drugs; 2012 Oct; 23(9):947-58. PubMed ID: 22713593
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles.
He X; Ma J; Mercado AE; Xu W; Jabbari E
Pharm Res; 2008 Jul; 25(7):1552-62. PubMed ID: 18196205
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.
Xu Q; Liu Y; Su S; Li W; Chen C; Wu Y
Biomaterials; 2012 Feb; 33(5):1627-39. PubMed ID: 22118775
[TBL] [Abstract][Full Text] [Related]
11. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
[TBL] [Abstract][Full Text] [Related]
12. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles.
Zhang Z; Feng SS
Biomaterials; 2006 Jul; 27(21):4025-33. PubMed ID: 16564085
[TBL] [Abstract][Full Text] [Related]
13. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
14. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
15. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
16. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethyleneglycol)-b-poly(ε-caprolactone-co-γ-hydroxyl-ε- caprolactone) bearing pendant hydroxyl groups as nanocarriers for doxorubicin delivery.
Chang L; Deng L; Wang W; Lv Z; Hu F; Dong A; Zhang J
Biomacromolecules; 2012 Oct; 13(10):3301-10. PubMed ID: 22931197
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E-Oligo(methyl diglycol l-glutamate) as a Biocompatible and Functional Surfactant for Facile Preparation of Active Tumor-Targeting PLGA Nanoparticles.
Wu J; Zhang J; Deng C; Meng F; Zhong Z
Biomacromolecules; 2016 Jul; 17(7):2367-74. PubMed ID: 27305935
[TBL] [Abstract][Full Text] [Related]
19. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.
Mi Y; Zhao J; Feng SS
J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
Lundberg BB
Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
